Hôpitaux Pédiatriques de Nice CHU-LENVAL Report issue

Academic/Hospital Phase 3

Organization Overview

First Clinical Trial
2018
NCT03525821
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2018

Timeline

NOW
  • Now

Alternative names

Hôpitaux Pédiatriques de Nice CHU-LENVAL

Active Ingredients

Drugs in Phase 3 Trials (2)

dexmedetomidine (precedex) (1 trial)

ketamine (ketalar) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Emergencies (Phase 3)

Fractures, Bone (Phase 3)

Fractures, Closed (Phase 3)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 2
  • # of Trial APIs: 2